MEQ Archives - Cambodia News Gazette

Market

Golden Meditech Announces the Disposal of Convertible Note Issued by CCBC for over US$88 million

HONG KONG, Aug. 25, 2014 /PRNewswire/ — Golden Meditech Holdings Limited (the “Company” or “Golden Meditech”, 801.HK; 910801.TW), a leading integrated healthcare enterprise in China, announced that it has entered into an agreement to sell its 7% senior convertible note due 2017 in an aggregate principal amount of US$50 million issued on 3 October 2012 by China Cord Blood Corporation (“CCBC”), a non-wholly-owned subsidiary of the Company (“Convertible Note”) to Magnum Opus International Holdings Limited (“Magnum”) and Cordlife Group Limited (“CGL”) for approximately US$88,090,000 (equivalent to approximately HK$682,697,500) in cash (the “Disposal”). Upon completion of the Disposal, each of Magnum and CGL will hold 50% of the Convertible Note.

Magnum is a private vehicle controlled by Mr. Kam Yuen, Chairman and Chief Executive Officer of the Company and Chairman of CCBC, and involves the CCBC management team. CGL is a cord blood banking services operator listed on the main board of the Singapore Exchange Securities Trading Limited, which currently owns approximately 10% of the issued shares of CCBC.

Following completion of the Disposal, Golden Meditech’s shareholding in CCBC will remain unchanged at approximately 42.0% and will only be diluted to approximately 33.9% if both Magnum and CGL exercise their rights to convert their Convertible Note into CCBC shares and, accordingly, their respective shareholdings in CCBC would increase by approximately 9.7%.

With mainland China’s healthcare sector continues to be driven by the government’s healthcare reform, Golden Meditech believes the Disposal would strengthen its financial position and liquidity, enhancing its ability to fund its potential acquisitions or expansion of its existing healthcare related businesses in mainland China.

The transaction is subject to Golden Meditech and CGL obtaining all relevant approvals and consents, including but not limited to the approval of Golden Meditech’s independent shareholders. An Extraordinary General Meeting (“EGM”) will be convened to consider and approve the transaction and a circular containing details of the Disposal and a notice of EGM are expected be dispatched to the shareholders no later than 16 September 2014.

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited (www.goldenmeditech.com) is China’s leading integrated-healthcare enterprise. Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets, including cord blood stem cells storage and hospital management, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China’s healthcare industry both through organic growth and strategic expansion.

Medical

ResMed Wins Initial Decision in ITC Patent Infringement Action

Judge Finds Nine BMC Products Infringe ResMed Patents

Judge Recommends Excluding U.S. Sale of BMC Masks and BMC Humidifier

SYDNEY and SAN DIEGO, Aug. 25, 2014 /PRNewswire/ — An administrative law judge at the International Trade Commission (ITC) ruled Friday August 22 in a patent infringement case brought by ResMed (NYSE: RMD) against Chinese medical device manufacturer BMC Medical Co., Ltd., that each of nine BMC products named in the action infringes one or more ResMed patents. As a result, ITC Judge Thomas Pender recommended that the ITC ban BMC and its U.S. distributor, 3B Medical, from importing or selling any of the infringing BMC products in the United States. Judge Pender also recommended a cease and desist order that would enjoin BMC and 3B from selling, advertising, marketing, storing or testing the infringing products in the United States. ResMed is the innovation leader and pioneer in designing and manufacturing devices for the treatment of sleep-disordered breathing.

Judge Pender found that BMC’s InH2 humidifier, as well as original and redesigned versions of the following BMC masks infringe ResMed’s patents:

iVolve nasal mask
iVolve N2 nasal mask
Willow nasal pillows mask
iVolve full face mask

“The Judge’s decision is not just a victory for ResMed and the product innovation that is core to our brand, but it’s also a win for patients who deserve high quality, comfortable care,” said David Pendarvis, ResMed chief administrative officer and global general counsel. “We will continue innovating and continue protecting our intellectual property anywhere we identify infringement.”

About ResMed:
ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contacts:
For News Media	For Investors
Gretchen Griswold	Agnes Lee
Director, Global Corporate Communications	Senior Director, Investor Relations
O: +1-858-836-6789	O: +1-858-836-5971
news@resmed.com	investorrelations@resmed.com

Logo – http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a

Medical

ProteinSimple Goes Big with the Simple Western

SANTA CLARA, Calif., July 21, 2014 /PRNewswire/ — ProteinSimple announced today that it has expanded the Simple Western product platform by launching a kit for the analysis of large proteins using Wes, Sally Sue and Peggy Sue. Now, Simple Western users can analyze proteins as large as 440 kDa while realizing all the benefits of the Simple Western — a fully automated, highly reproducible, truly quantitative assay.

The Simple Western eliminates a time-consuming bottleneck in protein research today — the Western blot. Traditional Westerns have real limitations. They require many manual steps, can take up to 24 hours to complete, and the results can be variable. The Simple Western eliminates the hassles of Western blot protocols – no messy gels, no transfer tanks, no blots, no imaging and no manual analysis. Simply load your samples, push a button, walk away and come back to fully analyzed, highly consistent data.

Until now, the Simple Western could analyze proteins up to 230 kDa in size. Now, with the introduction of the 66-440 kDa Master Kit, the Simple Western can quantify proteins as large as 440 kDa, giving researchers broader protein analysis capabilities with this platform.

“The Simple Western is rapidly becoming the technique of choice for users from a broad array of scientific disciplines and many have expressed the need for a broader size separation range,” commented John Proctor, Director of Marketing at ProteinSimple. “We are excited to deliver this kit to address their needs and expand the application of the Simple Western.”

Meet the entire Simple Western family at www.proteinsimple.com.